{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:23:00Z","timestamp":1790176980633,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.mehy.2012.03.026","type":"journal-article","created":{"date-parts":[[2012,4,28]],"date-time":"2012-04-28T20:22:25Z","timestamp":1335644545000},"page":"38-42","source":"Crossref","is-referenced-by-count":76,"title":["Antipsychotic drugs: Pro-cancer or anti-cancer? A systematic review"],"prefix":"10.1016","volume":"79","author":[{"given":"G.","family":"Fond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Macgregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Attal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Larue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ducasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Capdevielle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2012.03.026_b0005","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0269881107075509","article-title":"Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia","volume":"21","author":"Barnett","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.mehy.2012.03.026_b0010","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/archpsyc.64.2.242","article-title":"Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom\u2019s General Practice Research Database","volume":"64","author":"Osborn","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.mehy.2012.03.026_b0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.eurpsy.2007.07.002","article-title":"A well-being programme in severe mental illness. Reducing risk for physical ill-health: a post-programme service evaluation at 2years","volume":"22","author":"Smith","year":"2007","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.mehy.2012.03.026_b0020","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/cncr.21574","article-title":"Reduced cancer incidence among patients with schizophrenia","volume":"104","author":"Barak","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.mehy.2012.03.026_b0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1359786810382468","article-title":"Mortality in schizophrenia: a measurable clinical endpoint","volume":"24","author":"Bushe","year":"2009","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.mehy.2012.03.026_b0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.schres.2011.02.018","article-title":"The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study","volume":"129","author":"Chou","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.mehy.2012.03.026_b0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0920-9964(01)00308-5","article-title":"The association between schizophrenia and cancer: a population-based mortality study","volume":"57","author":"Cohen","year":"2002","journal-title":"Schizophr Res"},{"key":"10.1016\/j.mehy.2012.03.026_b0040","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1176\/appi.ajp.161.5.903","article-title":"Risk for cancer in parents of patients with schizophrenia","volume":"161","author":"Dalton","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.mehy.2012.03.026_b0045","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/sj.bjc.6601695","article-title":"Major life event \u2013 diagnosis of schizophrenia in offspring and risk for cancer","volume":"90","author":"Dalton","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.mehy.2012.03.026_b0050","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.ejca.2008.06.018","article-title":"Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994\u20132003: summary of findings","volume":"44","author":"Dalton","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.mehy.2012.03.026_b0055","first-page":"55","article-title":"Comorbidity of schizophrenia and cancer: clinical recommendations for treatment","volume":"18","author":"Damjanovic","year":"2006","journal-title":"Psychiatr Danub"},{"key":"10.1016\/j.mehy.2012.03.026_b0060","first-page":"597","article-title":"Cancer mortality in patients of psychiatric hospitals","volume":"107","author":"du Pan","year":"1977","journal-title":"Schweiz Med Wochenschr"},{"key":"10.1016\/j.mehy.2012.03.026_b0065","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1192\/bjp.187.4.334","article-title":"Schizophrenia and cancer: an epidemiological study","volume":"187","author":"Goldacre","year":"2005","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.mehy.2012.03.026_b0070","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.schres.2004.06.016","article-title":"Cancer in schizophrenia: is the risk higher or lower?","volume":"73","author":"Grinshpoon","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.mehy.2012.03.026_b0075","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/1359786810385489","article-title":"Cancer and schizophrenia: is there a paradox?","volume":"24","author":"Hodgson","year":"2010","journal-title":"J Psychopharmacol"},{"issue":"2004","key":"10.1016\/j.mehy.2012.03.026_b0080","first-page":"193","article-title":"The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations","volume":"30","author":"Lehman","year":"2003","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.mehy.2012.03.026_b0085","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1600-0447.2007.01095.x","article-title":"Physical illness and schizophrenia: a review of the literature","volume":"116","author":"Leucht","year":"2007","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.mehy.2012.03.026_b0090","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jad.2008.06.010","article-title":"The risk for cancer among patients with schizoaffective disorders","volume":"114","author":"Levav","year":"2009","journal-title":"J Affect Disord"},{"key":"10.1016\/j.mehy.2012.03.026_b0095","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1176\/appi.ajp.162.5.1024","article-title":"Cancer risk in parents of patients with schizophrenia","volume":"162","author":"Lichtermann","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.mehy.2012.03.026_b0100","first-page":"2999","article-title":"Relation between schizophrenia and cancer","volume":"149","author":"Mortensen","year":"1987","journal-title":"Ugeskr Laeger"},{"key":"10.1016\/j.mehy.2012.03.026_b0105","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1600-0447.1987.tb02839.x","article-title":"Neuroleptic treatment and other factors modifying cancer risk in schizophrenic patients","volume":"75","author":"Mortensen","year":"1987","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.mehy.2012.03.026_b0110","first-page":"1973","article-title":"Diagnosis of cancer and autopsy rate in schizophrenic patients","volume":"149","author":"Mortensen","year":"1987","journal-title":"Ugeskr Laeger"},{"key":"10.1016\/j.mehy.2012.03.026_b0115","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1600-0447.1992.tb10325.x","article-title":"Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients","volume":"85","author":"Mortensen","year":"1992","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.mehy.2012.03.026_b0120","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0920-9964(94)90028-0","article-title":"The occurrence of cancer in first admitted schizophrenic patients","volume":"12","author":"Mortensen","year":"1994","journal-title":"Schizophr Res"},{"key":"10.1016\/j.mehy.2012.03.026_b0125","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0447.1990.tb05466.x","article-title":"Mortality and causes of death in schizophrenic patients in Denmark","volume":"81","author":"Mortensen","year":"1990","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.mehy.2012.03.026_b0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0920-9964(02)00430-9","article-title":"Schizophrenia and the risk for breast cancer","volume":"62","author":"Oksbjerg Dalton","year":"2003","journal-title":"Schizophr Res"},{"key":"10.1016\/j.mehy.2012.03.026_b0135","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.urology.2006.08.1061","article-title":"Prostate cancer and schizophrenia","volume":"68","author":"Torrey","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.mehy.2012.03.026_b0140","unstructured":"U.S. Department of Health and Human Services,MA, July 1997."},{"key":"10.1016\/j.mehy.2012.03.026_b0145","unstructured":"FDA, <http:\/\/www.fda.gov.cder>."},{"key":"10.1016\/j.mehy.2012.03.026_b0150","unstructured":"Thomson PDR. Physicians\u2019 desk reference. 59th ed. Thomson Healthcare; 2005."},{"key":"10.1016\/j.mehy.2012.03.026_b0155","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0006-2952(99)00156-2","article-title":"Effects of psychotropic drugs on cell proliferation and differentiation","volume":"58","author":"Nordenberg","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.mehy.2012.03.026_b0160","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.tox.2009.04.056","article-title":"Genotoxic and carcinogenic effects of antipsychotics and antidepressants","volume":"261","author":"Brambilla","year":"2009","journal-title":"Toxicology"},{"key":"10.1016\/j.mehy.2012.03.026_b0165","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1432-1033.1995.tb20352.x","article-title":"Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability","volume":"228","author":"Drori","year":"1995","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.mehy.2012.03.026_b0170","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1248\/bpb.24.612","article-title":"Reversal of vinblastine resistance in human leukemic cells by haloperidol and dihydrohaloperidol","volume":"24","author":"Kataoka","year":"2001","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.mehy.2012.03.026_b0175","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ijc.24813","article-title":"Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target","volume":"126","author":"Wiklund","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.mehy.2012.03.026_b0180","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00280-003-0738-1","article-title":"Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes phenothiazines and leukemia","volume":"53","author":"Zhelev","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.mehy.2012.03.026_b0185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.critrevonc.2008.05.005","article-title":"Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies","volume":"69","author":"Argyriou","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.mehy.2012.03.026_b0190","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1385\/JMN:22:3:189","article-title":"Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumors","volume":"22","author":"Gil-Ad","year":"2004","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.mehy.2012.03.026_b0195","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/A:1006046604062","article-title":"The cell death response to gamma-radiation in MCF-7 cells is enhanced by a neuroleptic drug, pimozide","volume":"51","author":"Strobl","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.mehy.2012.03.026_b0200","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1742-2094-5-48","article-title":"Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection","volume":"5","author":"Hermes","year":"2008","journal-title":"J Neuroinflamm"},{"key":"10.1016\/j.mehy.2012.03.026_b0205","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1176\/ps.2007.58.10.1285","article-title":"Estimating Medicare Part D\u2019s impact on medication access among dually eligible beneficiaries with mental disorders","volume":"58","author":"Donohue","year":"2007","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.mehy.2012.03.026_b0210","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1021\/jm00011a013","article-title":"Hypoxia-selective antitumor agents. 10. bis(Nitroimidazoles) and related bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility","volume":"38","author":"Hay","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.mehy.2012.03.026_b0215","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1192\/bjp.181.4.321","article-title":"Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study","volume":"181","author":"McCreadie","year":"2002","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.mehy.2012.03.026_b0220","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/schbul\/sbn023","article-title":"Secondary effects of antipsychotics: women at greater risk than men","volume":"35","author":"Seeman","year":"2009","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.mehy.2012.03.026_b0225","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1403494807085192","article-title":"Cancer and the risk for taking early retirement pension: a Danish cohort study","volume":"36","author":"Carlsen","year":"2008","journal-title":"Scand J Public Health"},{"key":"10.1016\/j.mehy.2012.03.026_b0230","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1192\/S0007125000297080","article-title":"Cancer incidence of schizophrenic patients. Results of record linkage studies in three countries","author":"Gulbinat","year":"1992","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1016\/j.mehy.2012.03.026_b0235","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/sj.bjc.6603259","article-title":"Cancer risk among users of neuroleptic medication: a population-based cohort study","volume":"95","author":"Dalton","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.mehy.2012.03.026_b0240","first-page":"697","article-title":"Psychotropic medication use and risk of epithelial ovarian cancer","volume":"7","author":"Harlow","year":"1998","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.mehy.2012.03.026_b0245","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.schres.2010.08.035","article-title":"Clozapine treatment associated with increased risk of acute myeloid leukemia (AML)","volume":"123","author":"Nielsen","year":"2010","journal-title":"Schizophr Res"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987712001454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987712001454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T02:12:20Z","timestamp":1561687940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987712001454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0306987712001454"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2012.03.026","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}